Details

Autor(en) / Beteiligte

• Fahrmann, Johannes F
• Tanaka, Ichidai
• Irajizad, Ehsan
• Mao, Xiangying
• Dennison, Jennifer B
• Murage, Eunice
• Casabar, Julian
• Mayo, Jeffrey
• Peng, Qian
• Celiktas, Muge
• Vykoukal, Jody V
• Park, Soyoung
• Taguchi, Ayumu
• Delgado, Oliver
• Tripathi, Satyendra C
• Katayama, Hiroyuki
• Soto, Luisa Maren Solis
• Rodriguez-Canales, Jaime
• Behrens, Carmen
• Wistuba, Ignacio
• Hanash, Samir
• Ostrin, Edwin J

Titel

Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma

Ist Teil von

• Cancers, 2022-05, Vol.14 (10), p.2543

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Activation of the NRF2 pathway through gain-of-function mutations or loss-of-function of its suppressor KEAP1 is a frequent finding in lung cancer. NRF2 activation has been reported to alter the tumor microenvironment. Here, we demonstrated that NRF2 alters tryptophan metabolism through the kynurenine pathway that is associated with a tumor-promoting, immune suppressed microenvironment. Specifically, proteomic profiles of 47 lung adenocarcinoma (LUAD) cell lines (11 mutant and 36 wild-type) revealed the tryptophan-kynurenine enzyme kynureninase (KYNU) as a top overexpressed protein associated with activated NRF2. The siRNA-mediated knockdown of , the gene encoding for NRF2, or activation of the NRF2 pathway through siRNA-mediated knockdown of or via chemical induction with the NRF2-activator CDDO-Me confirmed that NRF2 is a regulator of KYNU expression in LUAD. Metabolomic analyses confirmed KYNU to be enzymatically functional. Analysis of multiple independent gene expression datasets of LUAD, as well as a LUAD tumor microarray demonstrated that elevated KYNU was associated with immunosuppression, including potent induction of T-regulatory cells, increased levels of PD1 and PD-L1, and resulted in poorer survival. Our findings indicate a novel mechanism of NRF2 tumoral immunosuppression through upregulation of KYNU.